chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia, Pain, Vaccination site pain
Clinical narrative: knee pain became very bad (joint and muscle); General body aches; Left arm (injection site) pain increased from elbow to shoulder; knee pain became very bad (joint and muscle); This is a spontaneous report from a contactable consumer, the patient. A 67-year-old male patient received his first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 17Mar2021 at 10:15 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included heart disease and arthritis in major joints and much of spine. The patient did not have allergies to medications, food, or other products. The patient received unspecified medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 20Mar2021 at 07:00, the patient experienced left arm pain at injection site which was increased from elbow to shoulder and knee pain became very bad (joint and muscle) and general body aches. The patient's both shoulder and knee already had bad arthritis. The patient reported that it took almost 72 hours to first develop joint and muscle aches and was especially bad in joints already with major arthritic related issues. All the events faded away after 02 days. The patient would get 2nd dose on 07Apr2021. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events left arm pain at injection site, knee pain became very bad (joint and muscle) and general body aches was resolved on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic
Clinical narrative: All over body rash - extremely itchy, burning and hot; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730), via an unspecified route of administration in the left arm on 21Mar2021 at 15:45 (at the age of 47-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously took sulfamethoxazole; trimethoprim (BACTRIM) for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 the patient experienced all over body rash which was extremely itchy, burning and hot. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the event rash pruritic was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Eye irritation, Ocular discomfort, Parosmia
Clinical narrative: Burning in left eye; Pressure in left eye; Constant cigarette smoke smell all the time; This is a spontaneous report from a contactable consumer, the patient. A 49-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on an unknown date in Mar2021 at 09:45 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The Patient had no Medical history reported. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN) 100mg once a day, vitamin b12 (MANUFACTURER UNKNOWN), and vitamin d (MANUFACTURER UNKNOWN); all from unknown date for unspecified indication. The patient did not have any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 31Mar2021 at 20:30 the patient experienced burning in left eye when sleeping at night, pressure in left eye during the day and constant cigarette smoke smell all the time. The clinical outcomes of the events burning in left eye, pressure in left eye and constant cigarette smoke smell all the time was not recovered.    No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Discomfort, Lymphadenopathy
Clinical narrative: Feel discomfort; Swollen lymph node under arm; This is a spontaneous report from a non-contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6206) via an unspecified route of administration in the left arm on 12Mar2021 at 11:00 (at the age of 41-year-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 02Apr2021 at 11:00 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. The patient did not have medical history. The patient did not have a history of allergies to medications, food or other products. Concomitant medication taken within two weeks included diazepam; isopropamide iodide (VALTRAX) received on unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. On unknown date in Mar2021, the patient experienced swollen lymph node under arm where vaccine was administered. It was reported that, after first dose lump appeared 3 to 4 days later and got bigger and experienced discomfort for almost two weeks and still it was a small lump (at the time of this report). On 02Apr2021 after second dose within 8 hours, the patient experienced swollen lymph node. It was reported that lump was swollen, size of baseball and the patient felt discomfort when she put her arm down by side. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events swollen lymph node under arm and feel discomfort were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Headache, Pain in extremity, Vaccination site swelling
Clinical narrative: Sharp left knee pain within a couple of hours and right knee pain the following day.; Left arm pain; swelling at incision site; Headache, exhaustion with first hour.; exhaustion with first hour; This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old non pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734), via an unspecified route of administration in the left arm on 27Mar2021 at 12:30 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, anaphylaxis several times, hives, patient was treated for mast cell activation syndrome symptoms, parvovirus infection, lyme disease, joint pain, melanoma, osteoporosis and small nodules on lungs which were watched and diagnosed as benign. The patient was allergic to birch, stone fruits, (i.e plums, cherries), eng, plaintain, peanuts, mould, dust, cats, dogs, grass, trees, ragweed, cockroach, mugwort plant, histamine and had chemical sensitivities to perfume, cologne, lotions, bleach, polyurethane, wood stains, could be anything. Concomitant medications included beclometasone dipropionate (QVAR) 80, salbutamol (ALBUTEROL), montelukast (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC), famotidine PEPCID for unknown indications from an unknown date received within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient had not been diagnosed with COVID-19. Since vaccination, the patient had not been tested for COVID-19. On 27Mar2021 at 13:45, the patient experienced left arm pain and swelling at injection site, headache, exhaustion with first hour, sharp left knee pain upon standing within a couple of hours that lasted at least a week. On 28Mar2021, patient experienced right knee pain the following day. Therapeutic measures were taken as the result of adverse events, which included treatment with tylenol 8 every 8 hours for a week to lessen all symptoms. The patient reported that arm pain went away and headache was not as bad but left knee pain was still there. The clinical outcome of the events painful left arm was recovered on an unknown date in 2021, the outcome of vaccination site swelling, headache, exhaustion and knee pain was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity
Clinical narrative: fatigue after 24 hours - lasting about 6 hours; Soreness in left arm for about 36 hours; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734 HNMC) via an unspecified route of administration in the left arm on 01Apr2021 at 14:00 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Concomitant medications included rosuvastatin calcium (CRESTOR) 10 mg (milligram), colecalciferol (NORDIC NATURALS VITAMIN D3) and New chap (MANUFACTURER UNKNOWN). The patient did not have any known allergy to any medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 15:00 the patient experienced soreness in left arm for about 36 hours and fatigue after 24 hours which was lasting about 6 hours. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events.  The clinical outcomes of the events fatigue was resolved on 02Apr2021, while that of soreness in left arm was resolved on 04Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swelling of lymph node above collar bone; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 27Mar2021 at 12:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included metformin (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN), vitamin d nos (MANUFACTURER UNKNOWN), probiotics (MANUFACTURER UNKNOWN), cyanocobalamin (B12); all for unknown indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 02Apr2021, the patient experienced swelling of lymph node above collar bone. It was unknown if the patient had received treatment for reported event. The adverse event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event swelling of lymph node above collar bone was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity
Clinical narrative: Arm/muscle soreness; Tired; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 02Apr2021 at 16:00 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have any allergies to medications, food, or other products. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021 at 19:00, the patient experienced arm/muscle soreness and tired. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events arm/muscle soreness and tired was recovering at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Muscular weakness, Paraesthesia
Clinical narrative: Tingling; weakness in hand; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 02Apr2021 at 11:30 (at the age of 51-years-old), as a single dose for COVID-19 immunisation. Medical history included allergy to some antibiotic. Concomitant medications included cannabidiol (CBD OIL), diclofenac (MANUFACTURER UNKNOWN), acetylsalicylic acid (BABY ASPIRIN) and famotidine (MANUFACTURER UNKNOWN); all for unspecified indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 11:30, 1-2 minutes after the shot, the patient experienced tingling in hand and weakness in hand which continued for 36 hours. The patient did not receive any treatment for the reported events. The clinical outcome of the event tingling and hands weakness of was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Bitter taste in mouth; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 02Apr2021 at 16:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included high cholesterol. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), calcium (MANUFACTURER UNKNOWN) and ascorbic acid; colecalciferol; zinc citrate; copper citrate; betacarotene; sodium; calcium; sodium selenite; zingiber officinale rhizome; andrographis paniculata; vitis vinifera seed; marrubium vulgare; propolis; bioflavonoids nos; allium sativum bulb; olea europaea leaf; echinacea purpurea root,;zinc ascorbate; pueraria lobata root; inula helenium root; polygonatum odoratum rhizome; hydrastis canadensis root; sambucus nigra fruit; astragalus mongholicus root; tabebuia impetiginosa bark; cinnamomum spp; bark,;angelica spp. root; isatis spp; eleutherococcus spp (HERBAL WELLNESS FORMULA). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 16:45, the patient experienced bitter taste in mouth about 10 minutes after receiving vaccine. It was reported that still present 14 hours later. The patient did not receive any treatment for the adverse event. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event bitter taste in mouth was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Muscular weakness, Pain, Proctalgia
Clinical narrative: Muscle pain in both legs; Weakness in both hands; Body aches; Rectal pain; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955), via an unspecified route of administration in the left arm on 28Mar2021 at 10:30 (at the age of 32-years-old), as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. The patient had no other medications in two weeks of receiving the vaccine. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since, the vaccination the patient had not been tested for COVID-19. On 31Mar2021 the patient experienced muscle pain in both legs, weakness in both hands, more pronounced in the left hand. Body aches and rectal pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for muscle pain in both legs, weakness of hands, ache and rectal pain. The clinical outcome of the events muscle pain in both legs, weakness of hands, ache, rectal pain was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Pain in extremity
Clinical narrative: Feel extremely dizzy; Tired; Arm was very sore; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 14:00 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Medical history included arthritis, herniated disc and regular headaches. The patient did not have allergies to medications, food, or other products. Concomitant medications included ethinylestradiol; norgestimate (SPRINTEC), vitamin d nos (VITAMIN D), fish oil (MANUFACTURER UNKNOWN) and magnesium (MANUFACTURER UNKNOWN), all medications received on unknown date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 14:45 after 45 minutes of vaccination, the patient experienced extremely dizzy and tired. The patient also experienced sore arm on the same day. It was also reported that she had started to feel extremely dizzy and tired which lasted for 2 to 3 hours, after which the dizziness went away but she still felt really tired and her arm was very sore for the two days following the injection. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported adverse events. The clinical outcome of events feel extremely dizzy was resolved on 31Mar2021 and arm was very sore was resolved on 02Apr2021, while that of tired was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Constipation, Fatigue, Inappropriate schedule of product administration, Nausea
Clinical narrative: Sore throat; Constipation; Intense abdominal pain; Fatigue; Nausea; inappropriate schedule of vaccine administered; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 19:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included Hashimoto's disease, vitamin D deficiency and 4 months postpartum. The patient was allergic to adhesive. Concomitant medication included colecalciferol (D3 (5000IU)) taken for unknown indication from unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 20:15 (at the age of 25-years-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. 03Apr2021, the patient experienced fatigue, nausea, sore throat, constipation and intense abdominal pain. The events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fatigue, nausea, sore throat, constipation and intense abdominal pain. The clinical outcome of the events fatigue, nausea, sore throat, constipation and intense abdominal pain were not resolved at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain
Clinical narrative: Sore throat; Constipation; Intense abdominal pain; Fatigue; Nausea; inappropriate schedule of vaccine administered; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 19:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included Hashimoto's disease, vitamin D deficiency and 4 months postpartum. The patient was allergic to adhesive. Concomitant medication included colecalciferol (D3 (5000IU)) taken for unknown indication from unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 20:15 (at the age of 25-years-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. 03Apr2021, the patient experienced fatigue, nausea, sore throat, constipation and intense abdominal pain. The events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fatigue, nausea, sore throat, constipation and intense abdominal pain. The clinical outcome of the events fatigue, nausea, sore throat, constipation and intense abdominal pain were not resolved at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain, Pyrexia, SARS-CoV-2 test
Clinical narrative: Fever; body aches; headache; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 29Mar2021 at 18:00 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Medical history included GERD (Gastroesophageal reflux disease). The patient did not have any allergies to medications, food, or other products. Concomitant medications included omeprazole (MANUFACTURER UNKNOWN), rizatriptan (MANUFACTURER UNKNOWN), magnesium (MANUFACTURER UNKNOWN), d and b (unspecified medication), all taken for unknown indications from unknown dates. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN), via an unspecified route of administration on unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 30Mar2021 at 17:30, the patient experienced fever, body aches and headaches. The patient did not receive any treatment for the reported events. The adverse events did not result in visit to doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. On 30Mar2021, the patient underwent rapid covid test (SARS-CoV-2 test, nasal swab) and the result was negative. The clinical outcome of the event fever, body aches and headache were recovered.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Pain in extremity, SARS-CoV-2 antibody test
Clinical narrative: arm soreness; Light headed; felt dizzy; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 03Apr2021 at 16:00(at the age of 34-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma and shortness of breath which lasted for three months. The patient had no allergies to food, medications or other products. Concomitant medications included lamotrigine (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021, at 21:00 the patient experienced felt dizzy and light-headed and at 22:00 she experienced arm soreness. It was reported that patient experienced dizzy/light headed at 21:00, again at 1:00, and again at 5:30, very brief and did not pass out and had arm soreness starting at around 10:00. On an unknown date, the patient underwent COVID-19 antibody test and the result was negative. The patient did not receive any treatment for the events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events felt dizzy, light-headed and arm soreness were recovering.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Chills, Diarrhoea, Migraine
Clinical narrative: fever; chills; migraine; night sweats; diarrhea; loss of taste; loss of smell; This is a spontaneous report from a contactable other healthcare professional, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 21Mar2021 at 16:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic pelvic pain, depression, anxiety, pudendal nerve neuralgia, endometriosis, and Factor V Leiden. The patient previously received prednisone (MANUFACTURER UNKNOWN), LEVOQUIN and CIPRO and experienced drug allergy. Concomitant medications included lamotrigine (LAMICTAL), venlafaxine hydrochloride (EFFEXOR SR), ondansetron (ZOFRAN), topiramate (TOPAMAX) and levorphanol (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: unknown) via an unspecified route of administration in the left arm on 28Feb2021 at 16:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 02Apr2021 at 14:00, around a week and half after the patient experienced fever, chills, migraine and night sweats, diarrhoea, loss of taste and loss of smell. The night sweats were for approximately 3-4 days after vaccine. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events fever, chills, migraine, night sweats, diarrhoea, loss of taste and loss of smell were resolving.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Night sweats, Pyrexia
Clinical narrative: fever; chills; migraine; night sweats; diarrhea; loss of taste; loss of smell; This is a spontaneous report from a contactable other healthcare professional, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 21Mar2021 at 16:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic pelvic pain, depression, anxiety, pudendal nerve neuralgia, endometriosis, and Factor V Leiden. The patient previously received prednisone (MANUFACTURER UNKNOWN), LEVOQUIN and CIPRO and experienced drug allergy. Concomitant medications included lamotrigine (LAMICTAL), venlafaxine hydrochloride (EFFEXOR SR), ondansetron (ZOFRAN), topiramate (TOPAMAX) and levorphanol (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: unknown) via an unspecified route of administration in the left arm on 28Feb2021 at 16:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 02Apr2021 at 14:00, around a week and half after the patient experienced fever, chills, migraine and night sweats, diarrhoea, loss of taste and loss of smell. The night sweats were for approximately 3-4 days after vaccine. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events fever, chills, migraine, night sweats, diarrhoea, loss of taste and loss of smell were resolving.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Dizziness, Feeling hot, Influenza like illness, Pain
Clinical narrative: Body aches; Chills; Dizzy; Felt like the flu was coming on; Felt very hot; Very blurry eyes; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: TW0150) via an unspecified route of administration in the left arm on 03Apr2021 at 14:00 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included bipolar disorder, depression and COVID-19. Concomitant medications included clonazepam (KLONOPIN) 10 milligram (mg) and testosterone (MANUFACTURER UNKNOWN) 200 mg. The patient did not have any known allergy to any medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021, immediately after vaccination, the patient experienced very blurry eyes. On the same day at 17:00, about 3 hours later, the patient experienced chills, dizzy and felt like the flu was coming on and all the night, the patient felt very hot with chills. Next day, on 04Apr2021, the patient had chills and body aches. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events very blurry eyes, chills, dizzy, felt like the flu, felt very hot and body aches. The clinical outcomes of the events very blurry eyes, chills, dizzy, felt like the flu, felt very hot and body aches were resolving at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: Body aches; Chills; Dizzy; Felt like the flu was coming on; Felt very hot; Very blurry eyes; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: TW0150) via an unspecified route of administration in the left arm on 03Apr2021 at 14:00 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included bipolar disorder, depression and COVID-19. Concomitant medications included clonazepam (KLONOPIN) 10 milligram (mg) and testosterone (MANUFACTURER UNKNOWN) 200 mg. The patient did not have any known allergy to any medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021, immediately after vaccination, the patient experienced very blurry eyes. On the same day at 17:00, about 3 hours later, the patient experienced chills, dizzy and felt like the flu was coming on and all the night, the patient felt very hot with chills. Next day, on 04Apr2021, the patient had chills and body aches. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events very blurry eyes, chills, dizzy, felt like the flu, felt very hot and body aches. The clinical outcomes of the events very blurry eyes, chills, dizzy, felt like the flu, felt very hot and body aches were resolving at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Stomatitis
Clinical narrative: swelling of under the tongue; This is a spontaneous report from a non-contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the arm left on 31Mar2021 at 08:30 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient was allergic to penicillins. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021, the patient experienced swelling of under the tongue. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the event swelling of under the tongue was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Rash macular
Clinical narrative: Red spots/ rash on chest; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 30Mar2021 (at the age of 51-years-old), as a single dose for COVID-19 immunisation. The patient's medical history was not reported. The patient previously took KENALOG for an unspecified indication and experienced drug allergy. Concomitant medications were not reported. It was unknown whether the patient was diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unspecified date in 2021, the patient experienced red spots/rash on chest. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event red spots/rash on chest was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Vitreous floaters
Clinical narrative: Black floaters in left eye; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 12:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included sertraline hydrochloride (ZOLOFT), trazodone (MANUFACTURER UNKNOWN), levothyroxine sodium (LEVOXYL) and amfetamine aspartate; amfetamine sulfate; dexamfetamine saccharate; dexamfetamine sulfate (ADDERALL), all for unknown indications from unknown dates and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine.  On 04Apr2021 at 00:30, the patient experienced black floaters in left eye. It got worse, than better, worse better and it was stable with some threads. The patient did not receive any treatment for the event black floaters in left eye. The clinical outcome of the event black floaters in left eye was not resolved at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing in ears-tinnitus; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the arm left on 27Mar2021 at 14:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. The patient did not receive any other medication within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the arm left on 06Mar2021 at 14:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 12:30, the patient experienced ringing in ears-tinnitus. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the ringing in ears was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Menstruation irregular, Pain, Pyrexia
Clinical narrative: Periods started 2 weeks early; Low grade fever; Body chills; Body ache; This is a spontaneous report from a non-contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ep6955) via an unspecified route of administration in the left arm on 01Apr2021 at 14:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not have any allergies to medications, food, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: en6204) via an unspecified route of administration in the left arm on 11Mar2021 at 15:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19.  Since the vaccination, the patient had not tested for COVID-19. On 02Apr2021 (10 hours after vaccination), the patient experienced low grade fever, body chills and body ache and lasted for a day. On 03Apr2021, the patient experienced periods started 2 weeks early on third day of vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment taken for the reported events. The clinical outcome of the events low grade fever, body chills and body ache resolved on an unknown date in Apr2021. The clinical outcome of periods started 2 weeks early was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Pain, Pyrexia
Clinical narrative: Aches; temperature 100 degrees F/Fever; Chills; Mild headache; This is a spontaneous report from a non-contactable consumer, the patient. A 61-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 02Apr2021 at 16:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history reported. The patient did not have any allergies to food, medications, or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 03Apr2021 (reported as next day), approximately 18 hours after the second dose, the patient had temperature 100 degrees Fahrenheit, aches, chills and mild headache. Fever broke 12 hours later and the patient felt great the next day (on 04Apr2021). The events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events aches, chills, temperature 100 degrees Fahrenheit/fever and mild headache. The clinical outcome of the events aches, chills and mild headache were resolved on 04Apr2021 while that of temperature 100 degrees Fahrenheit/fever was resolved on 03Apr2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, SARS-CoV-2 test
Clinical narrative: Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0150) via an unspecified route of administration in the left arm on 01Apr2021 at 18:00 (at the age of 53-years) as single dose for COVID-19 immunisation. Medical history included degenerative disc and bone disease, arthritis and patient had cough and congestion (not specified). The patient was allergic to PCN (penicillin), sulfa (sulfonamide), oxycodone, hydrocodone, gabapentin and diphtheria vaccine. Concomitant medications included naproxen (MANUFACTURER UNKNOWN), paracetamol (TYLENOL), alprazolam (XANAX) and escitalopram oxalate (LEXAPRO) for unknown indications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Apr2021 at 08:30, the patient experienced dizziness. The patient did not receive any treatment for the reported event. The adverse event result in doctor or other healthcare professional office or clinic visit. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event dizziness was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: constant tinnitus in left ear.; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 14:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included thyroid disorder. Concomitant medications included levothyroxine sodium (SYNTHROID) starting from an unknown date for an unknown indication. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 21Mar2021 at 14:00, 36 hours after vaccination, the  patient experienced constant tinnitus in left ear. The patient did not receive any treatment for the reported event. The clinical outcome of the event of constant tinnitus was not recovered at time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.